Teleflex Incorporated (NYSE:TFX) – Analysts at William Blair issued their Q1 2018 earnings per share estimates for Teleflex in a research report issued to clients and investors on Saturday. William Blair analyst B. Weinstein expects that the medical technology company will post earnings per share of $1.95 for the quarter. William Blair also issued estimates for Teleflex’s Q2 2018 earnings at $2.45 EPS, Q3 2018 earnings at $2.50 EPS and Q4 2018 earnings at $2.67 EPS.
Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, February 22nd. The medical technology company reported $2.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.40 by $0.04. Teleflex had a return on equity of 16.46% and a net margin of 7.11%. The firm had revenue of $595.10 million during the quarter, compared to analyst estimates of $601.17 million. During the same period last year, the company earned $2.13 EPS. Teleflex’s quarterly revenue was up 15.8% compared to the same quarter last year.
A number of other equities research analysts have also issued reports on TFX. ValuEngine lowered Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Stephens reissued a “buy” rating and set a $300.00 price target on shares of Teleflex in a research note on Thursday, January 18th. Leerink Swann reissued a “buy” rating and set a $321.00 price target (up from $307.00) on shares of Teleflex in a research note on Tuesday, January 30th. Finally, TheStreet downgraded Teleflex from an “a-” rating to a “c+” rating in a report on Monday, March 12th. One analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $281.56.
Shares of Teleflex (NYSE:TFX) opened at $265.28 on Tuesday. Teleflex has a one year low of $191.04 and a one year high of $288.78. The company has a current ratio of 2.33, a quick ratio of 1.51 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $11,927.25, a P/E ratio of 31.52, a P/E/G ratio of 1.96 and a beta of 1.22.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 15th. Shareholders of record on Friday, March 2nd were issued a dividend of $0.34 per share. The ex-dividend date was Thursday, March 1st. This represents a $1.36 annualized dividend and a yield of 0.51%. Teleflex’s payout ratio is currently 41.59%.
In other news, VP John Deren sold 1,359 shares of Teleflex stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $255.67, for a total value of $347,455.53. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $248.96, for a total value of $49,792.00. Following the completion of the transaction, the director now owns 8,080 shares in the company, valued at $2,011,596.80. The disclosure for this sale can be found here. Insiders have sold a total of 14,259 shares of company stock worth $3,760,536 over the last 90 days. 2.39% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in TFX. Victory Capital Management Inc. increased its holdings in shares of Teleflex by 15.9% in the 3rd quarter. Victory Capital Management Inc. now owns 8,488 shares of the medical technology company’s stock valued at $2,054,000 after acquiring an additional 1,163 shares during the period. Toronto Dominion Bank increased its holdings in shares of Teleflex by 244.4% in the 3rd quarter. Toronto Dominion Bank now owns 1,901 shares of the medical technology company’s stock valued at $460,000 after acquiring an additional 1,349 shares during the period. Rhumbline Advisers increased its holdings in shares of Teleflex by 8.5% in the 3rd quarter. Rhumbline Advisers now owns 94,156 shares of the medical technology company’s stock valued at $22,783,000 after acquiring an additional 7,395 shares during the period. Teacher Retirement System of Texas purchased a new position in shares of Teleflex in the 3rd quarter valued at $1,384,000. Finally, DekaBank Deutsche Girozentrale increased its holdings in shares of Teleflex by 9.7% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 3,396 shares of the medical technology company’s stock valued at $787,000 after acquiring an additional 301 shares during the period. Institutional investors and hedge funds own 90.75% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.thestockobserver.com/2018/03/21/equities-analysts-set-expectations-for-teleflex-incorporateds-q1-2018-earnings-tfx.html.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.